News

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the

While the direction of the stock markets is unpredictable, the growth of the aging population is entirely predictable. Along with an aging population come additional healthcare, beauty and

It’s not often that you see a company whose main product comes with a price tag of over $2 million, but that’s the case with biotechs BioMarin Pharmaceutical (NASDAQ: BMRN) and Sarepta

If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart. 

The stock gapped up nearly 28% on July 17, after

If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500. 

The top

If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500. 

The top

Pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly

The healthcare industry presents a fertile shopping ground for undervalued dividend stocks. S&P 500 components Pfizer Inc. (NYSE: PFE), Medtronic plc (NYSE: MDT) and Gilead Sciences Inc. (NASDAQ:

The healthcare industry presents a fertile shopping ground for undervalued dividend stocks. S&P 500 components Pfizer Inc. (NYSE: PFE), Medtronic plc (NYSE: MDT) and Gilead Sciences Inc. (NASDAQ:

The market's fear indicator, the VIX index, is bobbing along at long-term lows and gives little indication of a looming correction, but investors should assume one is brewing. The index is down at

Understanding insider buying is crucial for savvy investors looking to make informed decisions in the stock market. Insider buying occurs when company insiders, such as executives or directors,

The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with upcoming catalysts to watch. These

Major pharmaceutical companies including Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. (NYSE: MRK), Eli Lilly & Co. (NYSE: LLY) and 

Major pharmaceutical companies including Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. (NYSE: MRK), Eli Lilly & Co. (NYSE: LLY) and 

Major pharmaceutical companies including Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. (NYSE: MRK), Eli Lilly & Co. (NYSE: LLY) and